Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
2009-2-24
pubmed:abstractText
The current management of acute ischemic stroke is intravenous (IV) recombinant tissue plasminogen activator (rtPA). The presence of a hyperdense middle cerebral artery sign (HMCAS) on pre-treatment head computed tomogram (CT) is considered a poor prognostic sign. We compared the clinical outcome in IV rtPA-treated patients with and without a HMCAS.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
0317-1671
pubmed:author
pubmed:issnType
Print
pubmed:volume
35
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
583-7
pubmed:meshHeading
pubmed-meshheading:19235441-Acute Disease, pubmed-meshheading:19235441-Aged, pubmed-meshheading:19235441-Aged, 80 and over, pubmed-meshheading:19235441-Disability Evaluation, pubmed-meshheading:19235441-Emergency Medical Services, pubmed-meshheading:19235441-Female, pubmed-meshheading:19235441-Fibrinolytic Agents, pubmed-meshheading:19235441-Humans, pubmed-meshheading:19235441-Infarction, Middle Cerebral Artery, pubmed-meshheading:19235441-Injections, Intravenous, pubmed-meshheading:19235441-Logistic Models, pubmed-meshheading:19235441-Male, pubmed-meshheading:19235441-Middle Aged, pubmed-meshheading:19235441-Middle Cerebral Artery, pubmed-meshheading:19235441-Recombinant Fusion Proteins, pubmed-meshheading:19235441-Retrospective Studies, pubmed-meshheading:19235441-Stroke, pubmed-meshheading:19235441-Time, pubmed-meshheading:19235441-Tissue Plasminogen Activator, pubmed-meshheading:19235441-Treatment Outcome
pubmed:year
2008
pubmed:articleTitle
Acute stroke with hyperdense middle cerebral artery sign benefits from IV rtPA.
pubmed:affiliation
Department of Clinical Neurological Sciences, London Health Sciences Center, University of Western Ontario, London, ON, Canada.
pubmed:publicationType
Journal Article, Comparative Study